Eisai Co

Eisai Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Eisai Co (4523.T) as of Oct 29, 2026 is 40.21 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 72.89 B JPY — a change of -44.84% (lower).

EBITDA

40.21 BJPY

YoY

-44.84%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Eisai Co is 2026 40.21 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Eisai Co was 2025 72.89 B JPY. It decreases by -44.84% lower compared to the previous year.

The Eisai Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
112.68 B JPY
Jan 1, 2020
156.89 B JPY
Jan 1, 2021
75.81 B JPY
Jan 1, 2022
80.70 B JPY
Jan 1, 2023
62.37 B JPY
Jan 1, 2024
69.40 B JPY
Jan 1, 2025
72.89 B JPY
Jan 1, 2026
40.21 B JPY
The Eisai Co EBITDA history
YEAREBITDAYoY
40.21 BJPY-44.84%
72.89 BJPY+5.04%
69.40 BJPY+11.26%
62.37 BJPY-22.71%
80.70 BJPY+6.45%
75.81 BJPY-51.68%
156.89 BJPY+39.23%
112.68 BJPY+28.22%
87.88 BJPY+38.00%
63.68 BJPY+11.46%
57.13 BJPY+35.62%
42.13 BJPY-34.56%
64.37 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Eisai Co Stock analysis

What does Eisai Co do? Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company. Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries. Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world. The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases. Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA. Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery. Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields. Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable. Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Eisai Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Eisai Co is 40.21 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Eisai Co changed from 72.89 B JPY to 40.21 B JPY, representing a -44.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Eisai Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Eisai Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Eisai Co

All Key Metrics — Eisai Co